Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 3/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | GLS | O94925 | 1/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.40 |
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5868015 | 0.90 | CHRM4 (0.48) | OPRM1KCNH2ACHE | |
| SCHEMBL5868070 | 0.84 | SIGMAR1 (0.44) | KCNH2HRH3CHRM2CHRM5CHRM1 | |
| SCHEMBL5868096 | 0.84 | LTA4H (0.41) | CHRM2CHRM5CHRM1CHRM3FAAH | |
| SCHEMBL5867867 | 0.83 | KDM4E (0.57) | GRIN2B | |
| SCHEMBL5868136 | 0.83 | KDM1A (0.45) | CHRM2CHRM5CHRM1CHRM3F2 | |
| SCHEMBL5867995 | 0.82 | GRIN2B (0.48) | ACHEGRIN2B | |
| SCHEMBL5867974 | 0.79 | CHRM4 (0.46) | KCNH2CHRM2CHRM5CHRM1CHRM3 | |
| SCHEMBL5867969 | 0.79 | ACHE (0.52) | FAAHACHE | |
| SCHEMBL8623733 | 0.76 | ALDH1A1 (0.45) | PRSS1 | |
| SCHEMBL5868050 | 0.75 | CHRM4 (0.44) | KCNH2HRH3CHRM2CHRM5CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7053078-B2 | Serine protease inhibitors | ELI LILLY AND COMPANY (US) | 2006-05-30 | — | — | US | disclosed |
| EP-1289954-B1 | SERINE PROTEASE INHIBITORS | LILLY CO ELI (US) | 2005-09-14 | — | — | EP | disclosed |
| US-6900196-B2 | Serine protease inhibitors | ELI LILLY AND COMPANY (US) | 2005-05-31 | — | — | US | disclosed |
| US-20040259868-A1 | Serine protease inhibitors | LIEBESCHUETZ JOHN WALTER (GB) | 2004-12-23 | — | — | US | disclosed |
| US-20030109706-A1 | Serine pretease inhibitors | ELI LILLY AND COMPANY | 2003-06-12 | — | — | US | disclosed |
| EP-1289954-A1 | SERINE PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2003-03-12 | — | — | EP | disclosed |
| WO-2001096303-A1 | SERINE PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2001-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109706-A1 | Serine pretease inhibitors | PRSS1, SERPINE1, HPN | OPRM1 2707/4885KCNH2 3828/4885HRH3 3734/4885 |
| US-20040259868-A1 | Serine protease inhibitors | SERPINE1, PRSS1, SERPINB1 | OPRM1 2692/4885KCNH2 3744/4885HRH3 3417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.